Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-A1811 combined with pyrotinib or SHR-1316 in HER2-aberrant advanced non-small cell lung cancer
CTR20221887Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, pyrotinib, adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Sep 2022; status: active.
02
Drugs
trastuzumab rezetecanpyrotinibadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221887.